Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

3.8K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.8K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

2.0K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
2.0K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

917
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
917
Drug Discovery: Overview01:26

Drug Discovery: Overview

11.0K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.0K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

4.0K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

REM sleep fragmentation is associated with impaired configural threat learning.

Neurobiology of learning and memory·2026
Same author

Serotonin Transporter Blockade Reduces the Psychedelic-Like Effects of 4-Methoxy-<i>N</i>-methyl-<i>N</i>-isopropyltryptamine and Related Analogs.

ACS chemical neuroscience·2026
Same author

Serotonergic Polypharmacology of 2-Halogenated Tryptamines.

bioRxiv : the preprint server for biology·2026
Same author

Assessing the Potential Cardiovascular Risk of Microdosing the Psychedelic LSD in Mice.

ACS pharmacology & translational science·2026
Same author

Correction to "Next-Generation MDMA Analogue SDMA: Pharmacological and Metabolic Insights".

ACS chemical neuroscience·2026
Same author

Transforming Amino Acids into Serotonin 5-HT<sub>2A</sub> Receptor Ligands Using Photochemistry.

Journal of the American Chemical Society·2025

Related Experiment Video

Updated: Jan 16, 2026

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
09:09

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography

Published on: September 20, 2016

11.9K

Discovery of Highly Selective 5-HT2A Agonists Using Structure-Guided Design.

Tyler G Fenske1, John L McKee1, Natalie G Cavalco1

  • 1Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States.

Journal of Medicinal Chemistry
|September 25, 2025
PubMed
Summary

Researchers developed highly selective 5-HT2A agonists for studying psychedelic neurobiology. Structure-based design improved target engagement, advancing research into the mechanisms of psychedelic effects.

More Related Videos

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.2K
Harvesting and Cryo-cooling Crystals of Membrane Proteins Grown in Lipidic Mesophases for Structure Determination by Macromolecular Crystallography
18:45

Harvesting and Cryo-cooling Crystals of Membrane Proteins Grown in Lipidic Mesophases for Structure Determination by Macromolecular Crystallography

Published on: September 2, 2012

25.6K

Related Experiment Videos

Last Updated: Jan 16, 2026

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
09:09

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography

Published on: September 20, 2016

11.9K
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.2K
Harvesting and Cryo-cooling Crystals of Membrane Proteins Grown in Lipidic Mesophases for Structure Determination by Macromolecular Crystallography
18:45

Harvesting and Cryo-cooling Crystals of Membrane Proteins Grown in Lipidic Mesophases for Structure Determination by Macromolecular Crystallography

Published on: September 2, 2012

25.6K

Area of Science:

  • Neuroscience and Pharmacology
  • Medicinal Chemistry

Background:

  • Growing interest in psychedelics as neuroplastic therapies necessitates tools to study their mechanisms.
  • Developing selective serotonin 5-HT2A receptor agonists is crucial for understanding psychedelic effects.

Purpose of the Study:

  • To design and validate highly selective 5-HT2A receptor agonists.
  • To investigate structure-activity relationships for enhancing 5-HT2A target engagement.

Main Methods:

  • Structure-based drug design targeting residue L1232.53 in the 5-HT2A receptor.
  • Synthesis and characterization of novel N-benzyl scaffold compounds.
  • In vitro and in vivo assays including receptor binding, RNA editing isoform analysis, mutant receptor studies, ortholog testing, and mouse head-twitch response.

Main Results:

  • Achieved high selectivity for 5-HT2A over 5-HT2C by increasing steric bulk on the N-benzyl scaffold.
  • Comprehensive validation of selectivity across various assays and species orthologs.
  • Demonstrated rational design principles for optimizing 5-HT2A agonist target engagement.

Conclusions:

  • Highly selective 5-HT2A agonists can be rationally designed using structure-based approaches.
  • These novel compounds provide valuable tools for advancing the neurobiological study of psychedelics and their therapeutic potential.